Gabriel Byrne
About Gabriel Byrne
Gabriel Byrne is a Manager of Cell Culture Gene Therapy Process Development at Sangamo Therapeutics, Inc., with extensive experience in protein transport engineering and bioreactor operation. He holds a Bachelor's degree in Molecular Biology and is pursuing a PhD in Biomolecular Engineering from the University of California, Santa Cruz.
Current Role at Sangamo Therapeutics
Gabriel Byrne serves as the Manager of Cell Culture Gene Therapy Process Development at Sangamo Therapeutics, Inc. since 2021. In this role, he oversees the development and optimization of cell culture processes for gene therapy applications. His expertise in protein transport engineering plays a crucial role in advancing the company's capabilities in this area.
Previous Experience at JUST
Before joining Sangamo Therapeutics, Gabriel Byrne worked at JUST as a Process Scientist from 2019 to 2021 in San Francisco, California. During his tenure, he focused on process development related to cell culture, contributing to advancements in the production of biotherapeutics.
Educational Background
Gabriel Byrne studied at the University of California, Santa Cruz, where he earned a Bachelor's degree in Molecular, Cellular, and Developmental Biology. He later pursued a Doctor of Philosophy (PhD) in Biomolecular Engineering at the same institution, completing his studies in 2018. His academic background provides a strong foundation for his work in gene therapy and bioprocess development.
Expertise in Protein Engineering
Gabriel Byrne is proficient in custom antibody Fc design, which enhances therapeutic applications through altered effector functions and receptor binding. He has developed innovative methods for controlling glycosylation of recombinant proteins using CRISPR/Cas9 modifications to CHO glycan pathways, showcasing his technical skills in protein engineering.
Experience in Biomanufacturing
Gabriel Byrne has extensive experience in mammalian bioreactor operation, having worked across various levels of research, process development, clinical, and commercial manufacturing. He is familiar with cGMP document writing and tech transfer to both foreign and domestic Contract Manufacturing Organizations (CMOs), ensuring compliance and efficiency in production processes.